Universal Beteiligungs und Servicegesellschaft mbH Purchases 7,220 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 313,681 shares of the pharmaceutical company’s stock after acquiring an additional 7,220 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Vertex Pharmaceuticals worth $139,651,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. United Services Automobile Association bought a new stake in Vertex Pharmaceuticals during the first quarter worth $2,933,000. Lee Johnson Capital Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $721,000. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Vertex Pharmaceuticals by 3.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock worth $17,378,000 after purchasing an additional 1,393 shares during the last quarter. Bailard Inc. raised its holdings in shares of Vertex Pharmaceuticals by 0.5% in the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock valued at $16,983,000 after purchasing an additional 200 shares during the period. Finally, SteelPeak Wealth LLC acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $10,059,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $437.15 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68. The stock has a market capitalization of $110.91 billion, a price-to-earnings ratio of 31.25 and a beta of 0.36. The business’s fifty day moving average price is $408.04 and its two-hundred day moving average price is $427.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the company posted $4.38 earnings per share. Vertex Pharmaceuticals’s revenue was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on VRTX. Royal Bank Of Canada lowered their price target on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 4th. Canaccord Genuity Group reduced their target price on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research note on Wednesday, August 6th. Guggenheim dropped their price target on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a “market perform” rating for the company. Finally, Cantor Fitzgerald reduced their price objective on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $491.95.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.